• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌的当前及未来医学治疗综述
Cancers (Basel). 2024 Oct 15;16(20):3488. doi: 10.3390/cancers16203488.
2
Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.表皮生长因子受体靶向治疗 III 期和 IV 期头颈部癌症。
Curr Oncol. 2010 Jun;17(3):37-48. doi: 10.3747/co.v17i3.520.
3
Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.头颈部鳞状细胞癌中的免疫检查点抑制剂:3期临床试验的系统评价
World J Clin Oncol. 2022 May 24;13(5):388-411. doi: 10.5306/wjco.v13.i5.388.
4
The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC).免疫调节在治疗头颈部鳞状细胞癌(HNSCC)中的应用
Cells. 2024 Feb 27;13(5):413. doi: 10.3390/cells13050413.
5
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).癌症免疫治疗学会关于免疫治疗头颈部鳞状细胞癌(HNSCC)的共识声明。
J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5.
6
Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌临床管理的最新进展与未来方向
Cancers (Basel). 2021 Jan 18;13(2):338. doi: 10.3390/cancers13020338.
7
Immunotherapy in head and neck squamous cell carcinoma: An updated review.头颈部鳞状细胞癌的免疫治疗:最新综述
Cancer Treat Res Commun. 2022;33:100649. doi: 10.1016/j.ctarc.2022.100649. Epub 2022 Oct 14.
8
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.免疫治疗时代的头颈部癌症治疗:2023 年更新。
Drugs. 2023 Feb;83(3):217-248. doi: 10.1007/s40265-023-01835-2. Epub 2023 Jan 16.
9
Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.免疫疗法在复发性和转移性头颈部鳞状细胞癌患者中的应用。
Anticancer Agents Med Chem. 2019;19(3):290-303. doi: 10.2174/1871520618666180910092356.
10
Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.头颈部癌的免疫疗法——科学原理、当前治疗选择及未来方向。
Swiss Med Wkly. 2018 May 14;148:w14625. doi: 10.4414/smw.2018.14625. eCollection 2018.

引用本文的文献

1
Molecular Targets for Pharmacotherapy of Head and Neck Squamous Cell Carcinomas.头颈部鳞状细胞癌药物治疗的分子靶点
Curr Issues Mol Biol. 2025 Aug 1;47(8):609. doi: 10.3390/cimb47080609.
2
Unraveling the Role of Tumor-Infiltrating Immune Cells in Head and Neck Squamous Cell Carcinoma: Implications for Antitumor Immune Responses and Immunotherapy.解析头颈部鳞状细胞癌中肿瘤浸润免疫细胞的作用:对抗肿瘤免疫反应和免疫治疗的启示
Int J Mol Sci. 2025 Jun 30;26(13):6337. doi: 10.3390/ijms26136337.
3
C16orf74 is a novel prognostic biomarker and associates with immune infiltration in head and neck squamous cell carcinoma.C16orf74是一种新型的预后生物标志物,与头颈部鳞状细胞癌中的免疫浸润相关。
PLoS One. 2025 May 7;20(5):e0322701. doi: 10.1371/journal.pone.0322701. eCollection 2025.
4
Smell and Taste Impairments in Head and Neck Cancer Patients-A Scoping Review.头颈癌患者的嗅觉和味觉障碍——一项范围综述
Nutrients. 2025 Mar 20;17(6):1087. doi: 10.3390/nu17061087.
5
ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is associated with immune infiltration.ADORA2B促进头颈部鳞状细胞癌的增殖和迁移,并与免疫浸润相关。
BMC Cancer. 2025 Apr 12;25(1):673. doi: 10.1186/s12885-025-14102-2.
6
Nanotechnology in the perioperative treatment of head and neck cancer: application and outlook.纳米技术在头颈癌围手术期治疗中的应用与展望
Front Bioeng Biotechnol. 2025 Mar 27;13:1566522. doi: 10.3389/fbioe.2025.1566522. eCollection 2025.
7
Expression Influences Prognosis and Treatment Response in Head and Neck Squamous Cell Carcinoma.表达对头颈部鳞状细胞癌的预后和治疗反应有影响。
Cancers (Basel). 2025 Feb 8;17(4):587. doi: 10.3390/cancers17040587.

本文引用的文献

1
Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).铂类/紫杉类/帕博利珠单抗对比铂类/5-FU/帕博利珠单抗在复发性/转移性头颈部鳞状细胞癌(r/m HNSCC)中的应用。
Oral Oncol. 2024 Nov;158:106997. doi: 10.1016/j.oraloncology.2024.106997. Epub 2024 Aug 17.
2
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.帕博利珠单抗联合同步放化疗对比安慰剂联合同步放化疗用于局部晚期头颈部鳞状细胞癌患者(KEYNOTE-412):一项随机、双盲、3期试验
Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29.
3
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.INDUCE-2:一项评估 feladilimab 联合 tremelimumab 治疗晚期实体瘤患者的 I/II 期、开放标签、两部分研究。
Cancer Immunol Immunother. 2024 Feb 13;73(3):44. doi: 10.1007/s00262-023-03623-z.
4
Toll-like Receptor Agonists Are Unlikely to Provide Benefits in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.Toll样受体激动剂不太可能对头颈部鳞状细胞癌有益:一项系统评价和荟萃分析。
Cancers (Basel). 2023 Sep 1;15(17):4386. doi: 10.3390/cancers15174386.
5
SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.SGN-B6A:一种新型针对整合素β-6 的抗体药物偶联物,用于多种癌症适应证。
Mol Cancer Ther. 2023 Dec 1;22(12):1444-1453. doi: 10.1158/1535-7163.MCT-22-0817.
6
Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance.循环肿瘤组织改良病毒(TTMV)-HPV DNA 对 HPV 驱动型口咽癌监测的阴性预测值。
Clin Cancer Res. 2023 Oct 13;29(20):4306-4313. doi: 10.1158/1078-0432.CCR-23-1478.
7
Performance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus-Associated Oropharyngeal Cancer.液体活检在人乳头瘤病毒相关口咽癌诊断和监测中的应用。
JAMA Otolaryngol Head Neck Surg. 2023 Nov 1;149(11):971-977. doi: 10.1001/jamaoto.2023.1937.
8
Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌的流行病学、危险因素和预防。
Med Sci (Basel). 2023 Jun 13;11(2):42. doi: 10.3390/medsci11020042.
9
Rise of Antibody-Drug Conjugates: The Present and Future.抗体药物偶联物的兴起:现状与未来。
Am Soc Clin Oncol Educ Book. 2023 May;43:e390094. doi: 10.1200/EDBK_390094.
10
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.纳武利尤单抗联合伊匹单抗对比纳武利尤单抗单药治疗头颈部复发或转移性鳞状细胞癌的疗效和安全性:Ⅱ期 CheckMate 714 随机临床试验。
JAMA Oncol. 2023 Jun 1;9(6):779-789. doi: 10.1001/jamaoncol.2023.0147.

头颈部鳞状细胞癌的当前及未来医学治疗综述

Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma.

作者信息

Lee Aaron M, Weaver Alice N, Acosta Phillip, Harris Lauren, Bowles Daniel W

机构信息

Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO 80045, USA.

Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.

出版信息

Cancers (Basel). 2024 Oct 15;16(20):3488. doi: 10.3390/cancers16203488.

DOI:10.3390/cancers16203488
PMID:39456583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11506581/
Abstract

Head and neck squamous cell carcinoma (HNSCC) is a complex cancer requiring a multidisciplinary approach. For patients with locally or regionally advanced disease, surgery and/or radiation are the cornerstones of definitive treatment. Medical therapy plays an important adjunct role in this setting, typically consisting of a platinum-based regimen given as induction, concurrent, or adjuvant treatment. While relapsed/metastatic HNSCC has historically been a difficult-to-treat disease with poor outcomes, options have considerably improved with the incorporation of biologics and immune checkpoint inhibitors. Clinical trials are ongoing to investigate novel approaches, including new and combination immunotherapies, targeted therapies, therapeutic vaccines, antibody-drug conjugates, and cellular therapies. The results thus far have been mixed, highlighting the knowledge gaps that continue to challenge the medical oncologist treating HNSCC. Here, we present the most updated and broad review of the current treatment landscape in both locoregional and metastatic HNSCC and discuss the expansive future medical therapies under investigation.

摘要

头颈部鳞状细胞癌(HNSCC)是一种复杂的癌症,需要多学科方法进行治疗。对于局部或区域晚期疾病的患者,手术和/或放疗是确定性治疗的基石。药物治疗在这种情况下起着重要的辅助作用,通常包括以铂类为基础的方案,作为诱导、同步或辅助治疗。虽然复发性/转移性HNSCC历来是一种难以治疗且预后较差的疾病,但随着生物制剂和免疫检查点抑制剂的加入,治疗选择有了显著改善。正在进行临床试验以研究新的方法,包括新的和联合免疫疗法、靶向疗法、治疗性疫苗、抗体-药物偶联物和细胞疗法。迄今为止的结果喜忧参半,凸显了继续挑战治疗HNSCC的肿瘤内科医生的知识差距。在此,我们对头颈部局部区域和转移性HNSCC的当前治疗格局进行了最新且全面的综述,并讨论了正在研究的广泛的未来医学疗法。